Engraftment of primary AML, B-ALL and biphenotypic acute leukemia (BAL) patient samples was also evaluated and all patient samples could efficiently engraft, whereby the myeloid compartment of the BAL samples was better preserved in the human cytokine scaffold model. In conclusion, we show that we can genetically engineer the ectopic human BM microenvironment in our humanized scaffold xenograft model. This approach will be useful to functionally study the importance of niche factors for normal and malignant human hematopoiesis.
Abstract
Recently, NOD-SCID IL2Rγ −/− (NSG) mice were implanted with human mesenchymal stromal cells (MSCs) in the presence of ceramic scaffolds or matrigel in order to mimic the human bone marrow (BM) microenvironment. This approach allowed the engraftment of leukemic samples that failed to engraft in NSG mice without humanized niches and resulted in a better preservation of leukemic stem cell self-renewal properties [1] [2] [3] . To further improve our humanized niche scaffold model, we genetically engineered human MSCs to secrete human IL-3 and TPO. In vitro, these IL-3 and TPO-producing MSCs were superior in expanding human cord blood (CB) CD34 + hematopoietic stem/progenitor cells. MLL-AF9-transduced CB CD34 + cells could efficiently be transformed along myeloid or lymphoid lineages on IL-3 and TPOproducing MSCs. In vivo, these genetically engineered MSCs maintained their ability to differentiate into bone, adipocytes and various other stromal components. Upon transplantation of MLL-AF9-transduced cord blood CD34 + cells both AML and ALL developed in engineered scaffolds, whereby a significantly higher percentage of myeloid clones was observed in the mouse compartments compared to previous models.
Engraftment of primary AML, B-ALL and biphenotypic acute leukemia (BAL) patient samples was also evaluated and all patient samples could efficiently engraft, whereby the myeloid compartment of the BAL samples was better preserved in the human cytokine scaffold model. In conclusion, we show that we can genetically engineer the ectopic human BM microenvironment in our humanized scaffold xenograft model. This approach will be useful to functionally study the importance of niche factors for normal and malignant human hematopoiesis.
Introduction
Over the past decades, mouse xenograft models have significantly contributed to a better understanding of normal and malignant human hematopoiesis. The generation of immunodeficient mouse strains like the NOD-SCID IL2Rγ −/− (NSG) allowed researchers to functionally define human hematopoietic stem cells (HSCs) and their malignant counterpart [4] [5] [6] . These models also served as preclinical models for drug testing [7] .
Even though different subtypes of primary human acute myeloid leukemia (AML) samples can expand in these models, major limitations still exist as well. For 30-40% of AML samples engraftment remains challenging, especially for the favorable and intermediate risk groups [8] [9] [10] . This might be explained by the influence of the murine microenvironment and the absence of species-specific human factors. NOD-SCID and NSG transgenic mice expressing human factors such stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin-3 (IL-3), and thrombopoietin (TPO) have been developed and allowed an increase in the engraftability rate of primary AML samples [11] [12] [13] [14] . Furthermore, the expression of human SCF, GM-CSF and IL-3 allowed AML development upon transplantation of cord blood (CB) CD34 + cells expressing the MLL-AF9 oncogene [15] . More recently, a series of additional models have been developed [16] [17] [18] [19] [20] [21] [22] . For instance, MISTRG mice were developed whereby human macrophage colony-stimulating factor (M-CSF), IL-3, GM-CSF and TPO were knocked-in in their respective mouse loci, together with a BACtransgene encoding for human SIRP, supporting the development and function of innate immune cells in vivo [16] . 
Material and Methods

Humanized scaffold niche xenograft model
The ectopic bone model was established as described previously [1, 3, 23] . engraftment was analysed by timely sub-mandibular bleeding procedures. Cells isolated from patient #1 were enriched for CD34 as previously described [24, 25] . Cells isolated from patient #2 and #3 were CD3 depleted as previously described [1] .
MS5 and MSC co-cultures
CB CD34+ cells were grown in myeloid Gartner's without the ectopic addition of cytokines. CB MLL-AF9 cells were grown under myeloid restricted and lymphoid permissive conditions. More detailed information can be found in the supplementary methods.
Further materials and methods are provided as supplementary information.
Results
Characterization of IL-3 and TPO expressing MSCs in vitro and in vivo
We recently reported a human niche xenograft model in which MSCs are coated on scaffolds that are subcutaneously implanted in mice to generate humanized bone marrow niches [1, 3, 23] . Here, we wished to evaluate whether genetically engineered
MSCs can be used in this model and provide tools to perform gene-function analyses to study the importance of niche factors for normal and malignant human hematopoiesis.
Transcriptome studies of primary MSCs revealed that a variety of cytokines and growth factors are produced, but some critically important cytokines such IL-3 and TPO are not phosphorylation to comparable levels as stimulation with 1 ng/ml of these cytokines, suggesting that the concentration in conditioned media ranged from 10-50 pg/ml.
Similarly, MS5 lines were generated that produced IL-3 or TPO (cyto-MS5).
Next, stromal co-cultures were performed to functionally evaluate genetically previously (huBM-sc) [1] . Three different patient samples were investigated, including an AML, a B-ALL and a BAL sample (Supplemental Table 1 ). Leukemic CD34 + cells were injected between 6-8 weeks after subcutaneous implantation of the ectopic engineered BM niches. Efficient engraftment was observed for all leukemia samples in both the huBM-sc or cytoBM-sc models with comparable kinetics (Fig. 2A) (Fig. 2B) . B-ALL patient #2 contained an MLL-AF4 translocation with 99% CD19 + cells at diagnosis. For this sample, CD34-positivity of engrafting cells was better preserved in the cytoBM-sc model compared to the huBM-sc ( Fig. 2A) and murine niche environment (data not shown). Lastly, we analysed patient #3 who presented a BAL with complex karyotype (Supplemental Table 1 ). Overall, cells retrieved from the cytoBM-sc displayed an immunophenotype that or more closely resembled the phenotype of the patient at diagnosis, in particular with regard to expression levels of CD33 + and CD38 + ( Fig. 2A, 2C ). CB CD34 + cells transduced with MLL-AF9 can be transformed along the myeloid or lymphoid lineage depending on extrinsic cues [15, 27] . We have previously shown that while in the normal NSG xenograft model MLL-AF9-induced transformation in vivo is heavily lymphoid biased, more myeloid transformation is observed in the humanized niche scaffold model [3, 27] . Nevertheless, since in particular IL-3 was shown to be important for MLL-AF9 induced human AML in xenografts, and not produced by our MSCs (Fig. 1A) , we investigated the leukemic transformation potential of MLL-AF9
transduced CB CD34 + cells in our cytoBM-sc model.
To study this, we first cultured MLL-AF9-transduced CB cells in vitro on MSCs or a mixture of cyto-MSCs and MSCs supplemented with cytokines under myeloid-restricted or lymphoid permissive conditions. Rapid transformation was observed under all growth conditions (Fig. 3A) . We did not observe any differences in growth between the myeloidrestricted culture conditions and all cells remained CD33 + under both conditions ( Fig.   3A-B) . Under lymphoid-permissive conditions CB MLL-AF9 cells expanded faster on
MSCs with lymphoid cytokines compared to the cyto-MSCs (Fig. 3A) . CB MLL-AF9 cells underwent full lymphoid transformation on MSCs with the addition of lymphoid cytokines, whereas in the cyto-MSCs grown under lymphoid-permissive conditions both lymphoid and myeloid clones were expanding (Fig. 3C) . A typical feature of MLL-AF9 transformed cells is the formation of large cobblestone areas as was observed in both the normal MSC as well as the cyto-MSC co-cultures (Fig. 3D ). These data indicate that both MLL-AF9-induced myeloid as well as lymphoid transformation can be achieved in vitro on cyto-MSCs, whereby transformation appears to be more balanced towards the myeloid lineage compared to co-cultures on normal MSCs. 
Increased frequency of MLL-AF9-induced myeloid leukemia in cytoBM-sc implanted mice
We evaluated the in vivo MLL-AF9-driven leukemogenesis upon direct injection into cytoBM-sc NSG mice and compared that to our previously published models (intravenously (IV) injected NSG mice and scaffold injected (ISC) huBM-sc) (Fig. 4A) . In cytoBM-sc mice (n=11), 3 out of 4 implanted scaffolds were injected with 3x10 5 unsorted CB transduced MLL-AF9 cells, comparable to cell numbers that were injected into previously published IV or huBM-sc models. The transduction efficiency at the day of injection was approximately 15% (data not shown). All mice developed a fatal leukemia in 20-52 weeks, with a significantly longer latency compared to the previously used models (IV NSG vs cytoBM-sc: p=0.017, huBM-sc vs cytoBM-sc: p=0.046).
Unexpectedly, out of the 33 injected scaffolds only 8 scaffolds developed palpable tumors (24%), while in the huBM-sc model this percentage was 79% (Fig. 4B) .
Nevertheless, in all the injected cytoBM-sc that did not develop tumors, we could confirm the presence of human cells by IHC staining for CD45 + (Supplemental Fig. 2A ), of which a representative example is shown for mouse #5 cytoBM-sc1 (Fig. 4C ),
confirming that human cells were injected initially. The scaffold that did develop a tumor in mouse #5 (cytoBM-sc3) was analysed by IHC staining confirming positivity for CD45, CD33 and IL-3 (Fig. 4C) . Overall, the frequency of AML, B-ALL and mixed AML/B-ALL cells within the scaffolds was comparable between huBM-sc and cytoBM-sc models (Fig. 4D) .
We hypothesize that the lower rate of tumors formed on the scaffolds of cytoBM-sc mice might possibly be attributed to potentially high levels of exogenous IL-3 and TPO that would induce differentiation or loss of long-term self-renewal properties. As confirmed by IHC staining for the mouse endothelial marker CD31 and VwF, cytoBM-sc were well vascularized, allowing leukemic clones to migrate from the site of injection to mouse compartments (PB, BM, spleen, liver) (Supplemental Fig. 2B ). In fact, all mice developed an enlarged spleen, with an average weight of 0.82 ± 0.31 g (Supplemental Fig. 2C ). In contrast to our previous IV and huBM-sc models, differences in the leukemic phenotypes were observed in the mouse compartments. CD33 spleen, liver or BM had never been observed in any of our previous models (Fig. 4D , [3, 27] ). Furthermore, 20% of the mice displayed mixed B-ALL/AML clones in the spleen or liver, again a feature that was never observed in previous studies ( Fig. 4D-E [3,27] ).
In the murine BM niche, the mixed B-ALL/AML frequency was in line with what was observed in the previous models ( Fig. 4D-E) . MGG staining was performed on tissues to confirm the myeloid and/or lymphoid cells and a representative example of mouse #1
with mixed B-ALL/AML is shown (Fig. 4F ).
Although MSCs are not known to migrate efficiently from one organ to another, we questioned whether some MSCs might have migrated to the liver in the mouse that displayed exclusively AML cells (mouse #10). While we could detect the presence of CD45-expressing cells and IL-3, indicating engraftment of human cells as well as the presence of human IL-3, no tNGFR positive cells were detected (Fig. 4G) , providing no evidence for the migration of MSCs to the liver. Instead, tNGFR positive cells were detected in the scaffolds (Fig. 1J) . Overall, these data indicate that CB MLL-AF9 cells can engraft in the cytoBM-sc model albeit with longer latency and lower frequency, while in the organs of these mice the balance in lineage output is shifted somewhat towards more myeloid or mixed AML/B-ALL phenotypes. 
Lymphoid clones outcompete myeloid clones in secondary transplantation
In our previously published studies using the IV NSG and huBM-sc models, CB MLL-AF9 B-ALL cells could readily engraft in secondary recipients [3, 27] , while secondary engraftment of myeloid CD33 + clones was not achieved. 
Discussion
In order to improve the in vivo xenograft modelling of human hematological malignancies, several laboratories have begun to build humanized microenvironments in xenograft mice by making use of human mesenchymal stromal cells in order to provide better niches in which leukemic cells can engraft [1] [2] [3] 23, [28] [29] [30] [31] . In this study, we aimed to further develop our previously described huBM-sc model [1, 3, 23] These data indicate that these genetically engineered MSCs are sufficient to allow either myeloid or lymphoid transformation without the need for additional exogenous cytokines. Importantly, in the absence of exogenous cytokines, non-engineered MSCs or MS5 are not sufficient to allow in vitro transformation of MLL-AF9-transduced CB cells ( [27] and data not shown). We did notice that under lymphoid-permissive conditions the balance of MLL-AF9-induced transformation appeared to be shifted towards the myeloid lineage at later timepoints in comparison to when exogenous cytokines were added (Fig. 3C) .
Next, we assessed the ability of cyto-MSCs to differentiate in vivo. Six weeks after implantation, mice were sacrificed and scaffolds were analysed. No differences in the ability of forming bone, fat tissue and stromal component were observed compared to normal MSCs.
We then studied the engraftment of three primary AML, B-ALL and BAL patient samples in our new IL3/TPO-producing cytoBM-sc model to our previous huBM-sc models. All three tested samples efficiently engrafted in the cytoBM-sc model, with latencies and immunophenotypes that did not significantly differ from what we previously had observed in our huBM-sc model ( Fig.2 and [1] ). The main differences were that immature CD34 + cells for the B-ALL sample were better preserved in our new cytoBM-sc model, and the same was true for the myeloid CD33 + immune phenotype for the BAL patient sample. Furthermore, engraftment of MLL-AF9-transduced CB cells was evaluated in the new cytoBM-sc model since it had been shown that the lineage fate of MLL-AF9 expressing cells can be dictated by environmental cues [15, 27] , and we compared these data to our previous huBM-sc models and IV models [27] . and suggests that the presence of a modified human microenvironment that overexpresses IL-3 and TPO does not allow myeloid clones to self-renew properly, but a further fine-tuning of the levels of cytokines produced in the humanized niche might be required to solve these issues. The present study does clearly indicate that the humanized scaffold xenograft model allows for relatively simple genetic engineering of the bone marrow microenvironment. As such, this approach will be very useful to functionally study the importance of niche factors for normal and malignant human hematopoiesis.
